Description:
Mirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity
- Molecular Weight: 396.51
- Molecular Formula: C21H24N4O2S
Purity: 98%
Canonical SMILES:
C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI:
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N
- Boiling Point: 690.0±55.0 °C at 760 mmHg
- Melting Point: 138-145°C
- Appearance: White to yellowish powder
- Application: Adrenergic beta-3 Receptor Agonists
- Storage: Store in a tightly closed container , in a cool and dry place.
Synonyms:
YM-178; YM 178; YM178
More details are to be found on supplier website
